Sign In
Buy MNKD
$3.36
-0.0700 (-2.04%)
At Close: Jun 03, 2026
MannKind Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer
06:05am, Monday, 29'th Sep 2025
WESTLAKE VILLAGE, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale
MannKind Corporation (MNKD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
07:30pm, Wednesday, 10'th Sep 2025
MannKind Corporation (NASDAQ:MNKD ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 2:35 PM EDT Company Participants Michael Castagna - CEO & Director Conference Call Partic
MannKind Corporation (MNKD) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
09:55pm, Sunday, 07'th Sep 2025
MannKind Corporation (NASDAQ:MNKD ) Wells Fargo 20th Annual Healthcare Conference 2025 September 3, 2025 4:30 PM EDT Company Participants Michael Castagna - CEO & Director Conference Call Participants
MannKind Corporation (MNKD) Presents At Cantor Global Healthcare Conference 2025 Transcript
09:28pm, Sunday, 07'th Sep 2025
MannKind Corporation (NASDAQ:MNKD ) Cantor Global Healthcare Conference 2025 September 4, 2025 9:45 AM EDT Company Participants Michael Castagna - CEO & Director Conference Call Participants Olivia Br
MannKind to Present at Upcoming Investor Conferences
04:05pm, Wednesday, 27'th Aug 2025
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled
MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy
08:05am, Wednesday, 27'th Aug 2025
DANBURY, Conn. and BOSTON, Aug. 27, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced that United Therapeutics Corporation (Nasdaq: UTHR) has exercised its option—grante
New Strong Sell Stocks for August 27th
05:51am, Wednesday, 27'th Aug 2025
CVGI, INBK and MNKD have been added to the Zacks Rank #5 (Strong Sell) List on August 27, 2025.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of s
MannKind, Backed By Blackstone, Expands Cardiorenal Focus With $360 Million Deal
01:57pm, Monday, 25'th Aug 2025
MannKind Corporation MNKD on Monday agreed to acquire scPharmaceuticals Inc. SCPH for a deal value of up to approximately $360 million, or $5.35 per share.
MannKind Corporation (MNKD) Mergers and Acquisition Call Transcript
01:36pm, Monday, 25'th Aug 2025
MannKind Corporation (NASDAQ:MNKD ) Mergers and Acquisition Conference Call August 25, 2025 8:30 AM ET Company Participants Christopher B. Prentiss - Chief Financial Officer Michael E.
DANBURY, Conn. and BURLINGTON, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) and scPharmaceuticals Inc. (Nasdaq: SCPH) today announced the signing of a definitive merger
Acquisition expected to diversify and accelerate double-digit revenue growth with FUROSCIX ® , an innovative treatment for edema due to chronic heart failure and chronic kidney disease, addressing si
MannKind Corporation (MNKD) Q2 2025 Earnings Conference Call Transcript
05:20pm, Wednesday, 06'th Aug 2025
MannKind Corporation (NASDAQ:MNKD ) Q2 2025 Earnings Call August 6, 2025 9:00 AM ET Company Participants Christopher B. Prentiss - Chief Financial Officer Michael E.
MannKind Corporation: A Post-Q2 Assessment
04:44pm, Wednesday, 06'th Aug 2025
Today, we take another look at MannKind Corporation, which specializes in inhaled therapeutics for endocrine and orphan lung diseases, with a market cap of $1.15 billion. The company just reported sec
